Key result
B cells contribute to cardiac hypertrophy, inflammation, and maladaptive tissue remodeling, suggesting that immunomodulatory therapies targeting B cells, such as rituximab, may offer novel treatment strategies for heart failure.
Why the study?
Emerging evidence indicates B cells participate in cardiovascular diseases, prompting evaluation of B-cell targeted immunomodulatory strategies for heart failure.
Answers are grounded in this paper and cite their sources.
This review proposes that targeting B cells and their products may serve as a novel immunomodulatory therapeutic strategy for heart failure.
Cardio-oncology, a nascent specialty, has evolved as a concerted strategy to address the cardiovascular complications of cancer therapies. On the other hand, emerging evidence has shown that some anti-tumor drugs, such as CD20-targeted rotuximab, also have markedly cardioprotective effects in addition to treating cancers. Rituximab is a CD20-targeted monoclonal antibody and kill tumor B-cells through antibody-mediated and antibody-independent pathways, indicating that B cells participate and promote the progression of cardiovascular diseases. In this review, we mainly present the evidence that B cells contribute to the development of hypertrophy, inflammation, and maladaptive tissue remodeling, with the aim of proposing novel immunomodulatory therapeutic strategies targeting B cells and their products for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a review in Heart Failure. Immunomodulatory Treatment Strategies Targeting B Cells (e.g., Rituximab) was evaluated. B cells contribute to cardiac hypertrophy, inflammation, and maladaptive tissue remodeling, suggesting that immunomodulatory therapies targeting B cells, such as rituximab, may offer novel treatment strategies for heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: